Economic implications of using pegfilgrastim rather than conventional G-CSF to prevent neutropenia during small-cell lung cancer chemotherapy

ABSTRACT Background: For the prevention of chemotherapy-induced febrile aplasia, a single injection of pegfilgrastim per cycle has the same efficacy as six to ten injections of conventional granulocyte colony-stimulating factor (G-CSF). However, there are few data on the economic impact of pegfilgra...

Full description

Saved in:
Bibliographic Details
Published in:Current medical research and opinion 2009-06, Vol.25 (6), p.1455-1460
Main Authors: Tan Sean, P., Chouaid, C., Hettler, D., Baud, M., Hejblum, G., Tilleul, P.
Format: Article
Language:English
Subjects:
Adult
Antineoplastic Combined Chemotherapy Protocols
Antineoplastic Combined Chemotherapy Protocols - adverse effects
Antineoplastic Combined Chemotherapy Protocols - therapeutic use
Cost of Illness
Female
Filgrastim
Granulocyte Colony-Stimulating Factor
Granulocyte Colony-Stimulating Factor - economics
Granulocyte Colony-Stimulating Factor - therapeutic use
Health Care Costs
Humans
Life Sciences
Lung Neoplasms
Lung Neoplasms - drug therapy
Lung Neoplasms - economics
Male
Middle Aged
Models, Economic
Neutropenia
Neutropenia - chemically induced
Neutropenia - economics
Neutropenia - prevention & control
Patient Acceptance of Health Care
Polyethylene Glycols
Recombinant Proteins
Retrospective Studies
Santé publique et épidémiologie
Small Cell Lung Carcinoma
Small Cell Lung Carcinoma - drug therapy
Small Cell Lung Carcinoma - economics
Socioeconomic Factors
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:ABSTRACT Background: For the prevention of chemotherapy-induced febrile aplasia, a single injection of pegfilgrastim per cycle has the same efficacy as six to ten injections of conventional granulocyte colony-stimulating factor (G-CSF). However, there are few data on the economic impact of pegfilgrastim use, especially in the context of small-cell lung cancer. Methods: This retrospective study involved 31 patients and 129 treatment cycles (32 with pegfilgrastim and 97 with granulocyte colony-stimulating factor (G-CSF)). We estimated the direct costs for preventing and managing febrile aplasia from the payer's perspective and also conducted a willingness-to-pay study with 100 healthy subjects, in order to estimate how highly a single-jab strategy was valued relative to multiple injections. Results: The costs per cycle were respectively €1743 ± 837 and €1466 ± 836 for the pegfilgrastim and G-CSF strategies (p 
ISSN:0300-7995
1473-4877
DOI:10.1185/03007990902918156